{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:08:24Z","timestamp":1794809304638,"version":"4.9.1"},"reference-count":64,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\u03b1-Fetoprotein (AFP) is expressed by stem-like and poor outcome hepatocellular cancer tumors and is a clinical tumor biomarker. AFP has been demonstrated to inhibit dendritic cell (DC) differentiation and maturation and to block oxidative phosphorylation. To identify the critical metabolic pathways leading to human DC functional suppression, here, we used two recently described single-cell profiling methods, scMEP (single-cell metabolic profiling) and SCENITH (single-cell energetic metabolism by profiling translation inhibition). Glycolytic capacity and glucose dependence of DCs were significantly increased by tumor-derived, but not normal cord blood\u2013derived, AFP, leading to increased glucose uptake and lactate secretion. Key molecules in the electron transport chain in particular were regulated by tumor-derived AFP. These metabolic changes occurred at mRNA and protein levels, with negative impact on DC stimulatory capacity. Tumor-derived AFP bound significantly more polyunsaturated fatty acids (PUFA) than cord blood\u2013derived AFP. PUFAs bound to AFP increased metabolic skewing and promoted DC functional suppression. PUFAs inhibited DC differentiation in vitro, and \u03c9-6 PUFAs conferred potent immunoregulation when bound to tumor-derived AFP. Together, these findings provide mechanistic insights into how AFP antagonizes the innate immune response to limit antitumor immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>\u03b1-Fetoprotein (AFP) is a secreted tumor protein and biomarker with impact on immunity. Fatty acid\u2013bound AFP promotes immune suppression by skewing human dendritic cell metabolism toward glycolysis and reduced immune stimulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-22-3551","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T09:51:26Z","timestamp":1677491486000},"page":"1543-1557","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Polyunsaturated Fatty Acid\u2013Bound \u03b1-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism"],"prefix":"10.1158","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2701-7833","authenticated-orcid":false,"given":"Paul V.","family":"Munson","sequence":"first","affiliation":[{"name":"1Parker Institute for Cancer Immunotherapy, San Francisco, California."},{"name":"2Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-158X","authenticated-orcid":false,"given":"Juraj","family":"Adamik","sequence":"additional","affiliation":[{"name":"1Parker Institute for Cancer Immunotherapy, San Francisco, California."},{"name":"2Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-2276","authenticated-orcid":false,"given":"Felix J.","family":"Hartmann","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Stanford University, Stanford, California."},{"name":"4Systems Immunology and Single-Cell Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany."},{"name":"5Department of Pathology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-9538","authenticated-orcid":false,"given":"Patricia M.B.","family":"Favaro","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Stanford University, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8608-8426","authenticated-orcid":false,"given":"Daniel","family":"Ho","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Stanford University, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1341-2453","authenticated-orcid":false,"given":"Sean C.","family":"Bendall","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Stanford University, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9110-6542","authenticated-orcid":false,"given":"Alexis J.","family":"Combes","sequence":"additional","affiliation":[{"name":"6ImmunoProfiler Initiative, University of California San Francisco, San Francisco, California."},{"name":"7Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7915-3533","authenticated-orcid":false,"given":"Matthew F.","family":"Krummel","sequence":"additional","affiliation":[{"name":"6ImmunoProfiler Initiative, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-9977","authenticated-orcid":false,"given":"Karen","family":"Zhang","sequence":"additional","affiliation":[{"name":"7Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin K.","family":"Kelley","sequence":"additional","affiliation":[{"name":"7Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California."},{"name":"8Department of Medicine (Hematology\/Oncology), University of California, San Francisco, California."},{"name":"9Cancer Immunotherapy Program, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3439-9844","authenticated-orcid":false,"given":"Lisa H.","family":"Butterfield","sequence":"additional","affiliation":[{"name":"1Parker Institute for Cancer Immunotherapy, San Francisco, California."},{"name":"2Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"2025112417481764300_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025112417481764300_bib2","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2025112417481764300_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2017.03.011","article-title":"Global trends and predictions in hepatocellular carcinoma mortality","volume":"67","author":"Bertuccio","year":"2017","journal-title":"J Hepatol"},{"key":"2025112417481764300_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"48","author":"R Team","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"2025112417481764300_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"2025112417481764300_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"2025112417481764300_bib7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"2025112417481764300_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112417481764300_bib9","first-page":"695","article-title":"Atezolizumab and bevacizumab in hepatocellular carcinoma. reply","volume":"383","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112417481764300_bib10","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025112417481764300_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025112417481764300_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2025112417481764300_bib13","doi-asserted-by":"crossref","first-page":"267\u2013","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112417481764300_bib14","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112417481764300_bib15","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112417481764300_bib16","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"2025112417481764300_bib17","doi-asserted-by":"crossref","first-page":"12870","DOI":"10.1038\/s41598-017-12834-1","article-title":"The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma","volume":"7","author":"Bai","year":"2017","journal-title":"Sci Rep"},{"key":"2025112417481764300_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.seminoncol.2012.05.003","article-title":"Gene signatures in the management of hepatocellular carcinoma","volume":"39","author":"Hoshida","year":"2012","journal-title":"Semin Oncol"},{"key":"2025112417481764300_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41416-019-0513-7","article-title":"Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials","volume":"121","author":"Montal","year":"2019","journal-title":"Br J Cancer"},{"key":"2025112417481764300_bib20","first-page":"90","article-title":"[Detection of embryo-specific alpha-globulin in the blood serum of a patient with primary liver cancer]","volume":"10","author":"Tatarinov","year":"1964","journal-title":"Vopr Med Khim"},{"key":"2025112417481764300_bib21","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1158\/1078-0432.CCR-19-3884","article-title":"Serum alpha-fetoprotein levels and clinical outcomes in the phase III CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma","volume":"26","author":"Kelley","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112417481764300_bib22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1572-0241.2006.00443.x","article-title":"Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?","volume":"101","author":"Farinati","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"2025112417481764300_bib23","first-page":"3134","article-title":"Generation of human T-cell responses to an HLA-A2.1\u2013restricted peptide epitope derived from alpha-fetoprotein","volume":"59","author":"Butterfield","year":"1999","journal-title":"Cancer Res"},{"key":"2025112417481764300_bib24","first-page":"5902","article-title":"T-cell responses to HLA-A*0201 immunodominant peptides derived from \u03b1-fetoprotein in patients with hepatocellular cancer","volume":"9","author":"Butterfield","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025112417481764300_bib25","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-05-2856","article-title":"A phase I\/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides","volume":"12","author":"Butterfield","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025112417481764300_bib26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/2326-6066.CIR-16-0216","article-title":"Tumor-derived \u03b1-fetoprotein directly drives human natural killer\u2013cell activation and subsequent cell death","volume":"5","author":"Vujanovic","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2025112417481764300_bib27","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.4049\/jimmunol.132.4.1722","article-title":"Alpha-fetoprotein inhibits macrophage expression of Ia antigens","volume":"132","author":"Lu","year":"1984","journal-title":"J Immunol"},{"key":"2025112417481764300_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0008-8749(86)90154-1","article-title":"\u03b1-Fetoprotein stimulates leukotriene synthesis in P388D1 macrophages","volume":"101","author":"Aussel","year":"1986","journal-title":"Cell Immunol"},{"key":"2025112417481764300_bib29","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.4049\/jimmunol.1400725","article-title":"Tumor-derived \u03b1-fetoprotein impairs the differentiation and T-cell stimulatory activity of human dendritic cells","volume":"193","author":"Pardee","year":"2014","journal-title":"J Immunol"},{"key":"2025112417481764300_bib30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/2326-6066.CIR-18-0513","article-title":"Tumor-derived \u03b1-fetoprotein suppresses fatty acid metabolism and oxidative phosphorylation in dendritic cells","volume":"7","author":"Santos","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2025112417481764300_bib31","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1002\/hep.30477","article-title":"Tuning T-cell receptor affinity to optimize clinical risk-benefit when targeting alpha-fetoprotein\u2013positive liver cancer","volume":"69","author":"Docta","year":"2019","journal-title":"Hepatology"},{"key":"2025112417481764300_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hep.29844","article-title":"Identification of \u03b1-fetoprotein\u2013specific T-cell receptors for hepatocellular carcinoma immunotherapy","volume":"68","author":"Zhu","year":"2018","journal-title":"Hepatology"},{"key":"2025112417481764300_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ijc.2910340304","article-title":"Evaluation of AFP glycosylation heterogeneity in cancer patients with AFP-producing tumors","volume":"34","author":"Vessella","year":"1984","journal-title":"Int J Cancer"},{"key":"2025112417481764300_bib34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/1097-0142(19880215)61:4<769::AID-CNCR2820610422>3.0.CO;2-M","article-title":"The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma","volume":"61","author":"Aoyagi","year":"1988","journal-title":"Cancer"},{"key":"2025112417481764300_bib35","first-page":"2927","article-title":"AFP isoforms and their clinical significance (overview)","volume":"17","author":"Lamerz","year":"1997","journal-title":"Anticancer Res"},{"key":"2025112417481764300_bib36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/153537020122600503","article-title":"Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants","volume":"226","author":"Mizejewski","year":"2001","journal-title":"Exp Biol Med Maywood NJ"},{"key":"2025112417481764300_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/1097-0142(19940701)74:1<25::AID-CNCR2820740106>3.0.CO;2-U","article-title":"Detection of hepatocellular carcinoma- specific alpha-fetoprotein by isoelectric focusing","volume":"74","author":"Burditt","year":"1994","journal-title":"Cancer"},{"key":"2025112417481764300_bib38","first-page":"27","article-title":"High affinity of nonesterified polyunsaturated fatty acids for rat alpha-fetoprotein (AFP)","volume":"1","author":"Benassayag","year":"1980","journal-title":"Oncodev Biol Med"},{"key":"2025112417481764300_bib39","first-page":"85","article-title":"Human alpha-fetoprotein and albumin: differences in zinc binding","volume":"5","author":"Wu","year":"1987","journal-title":"Clin Physiol Biochem"},{"key":"2025112417481764300_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-4439(01)00079-5","article-title":"Human alpha-fetoprotein as a Zn(2+)-binding protein. Tight cation binding is not accompanied by global changes in protein structure and stability","volume":"1586","author":"Permyakov","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"2025112417481764300_bib41","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","article-title":"SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution","volume":"32","author":"Arg\u00fcello","year":"2020","journal-title":"Cell Metab"},{"key":"2025112417481764300_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41587-020-0651-8","article-title":"Single-cell metabolic profiling of human cytotoxic T cells","volume":"39","author":"Hartmann","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2025112417481764300_bib43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1471-2105-10-106","article-title":"Bioconductor package for high throughput flow cytometry","volume":"10","author":"Hahne","year":"2009","journal-title":"BMC Bioinformatics."},{"key":"2025112417481764300_bib44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Research."},{"key":"2025112417481764300_bib45","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","article-title":"Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)","volume":"47","author":"Raudvere","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2025112417481764300_bib46","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1194\/jlr.M009449","article-title":"Lipidomics reveals a remarkable diversity of lipids in human plasma","volume":"51","author":"Quehenberger","year":"2010","journal-title":"J Lipid Res"},{"key":"2025112417481764300_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbalip.2017.11.006","article-title":"Cell culture models of fatty acid overload: problems and solutions","volume":"1863","author":"Alsabeeh","year":"2018","journal-title":"Biochim Biophys Acta"},{"key":"2025112417481764300_bib48","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1038\/s41467-022-32849-1","article-title":"Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells","volume":"13","author":"Adamik","year":"2022","journal-title":"Nat Commun"},{"key":"2025112417481764300_bib49","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/S0021-9258(17)38047-X","article-title":"The presence of fatty acids in human alpha-fetoprotein","volume":"253","author":"Parmelee","year":"1978","journal-title":"J Biol Chem"},{"key":"2025112417481764300_bib50","first-page":"1864","article-title":"Zinc induces dendritic cell tolerogenic phenotype and skews regulatory T-cell-Th17 balance","volume":"197","author":"George","year":"2016","journal-title":"J Immunol Baltim Md 1950"},{"key":"2025112417481764300_bib51","doi-asserted-by":"crossref","first-page":"14293","DOI":"10.1074\/jbc.M410000200","article-title":"Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-\u03baB activation","volume":"280","author":"Zeyda","year":"2005","journal-title":"J Biol Chem"},{"key":"2025112417481764300_bib52","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.174.9.5390","article-title":"Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4","volume":"174","author":"Weatherill","year":"2005","journal-title":"J Immunol"},{"key":"2025112417481764300_bib53","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmet.2018.03.014","article-title":"Evidence that TLR4 is not a receptor for saturated fatty acids but mediates lipid-induced inflammation by reprogramming macrophage metabolism","volume":"27","author":"Lancaster","year":"2018","journal-title":"Cell Metab"},{"key":"2025112417481764300_bib54","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1084\/jem.185.10.1743","article-title":"A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing","volume":"185","author":"Cella","year":"1997","journal-title":"J Exp Med"},{"key":"2025112417481764300_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0966-3274(03)00058-3","article-title":"High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells","volume":"11","author":"Manavalan","year":"2003","journal-title":"Transpl Immunol"},{"key":"2025112417481764300_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ni760","article-title":"Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4","volume":"3","author":"Chang","year":"2002","journal-title":"Nat Immunol"},{"key":"2025112417481764300_bib57","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/gt.2013.80","article-title":"Interference with PD-L1\/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells","volume":"21","author":"Pen","year":"2014","journal-title":"Gene Ther"},{"key":"2025112417481764300_bib58","first-page":"712","article-title":"Hierarchy of alpha fetoprotein (AFP)-specific T-cell responses in subjects with AFP-positive hepatocellular cancer","volume":"177","author":"Liu","year":"2006","journal-title":"J Immunol Baltim Md 1950"},{"key":"2025112417481764300_bib59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/14712598.8.3.325","article-title":"Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer","volume":"8","author":"Evdokimova","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"2025112417481764300_bib60","first-page":"425","article-title":"AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients","volume":"30","author":"Evdokimova","year":"2007","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"2025112417481764300_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41577-020-0406-2","article-title":"Lactate modulation of immune responses in inflammatory versus tumour microenvironments","volume":"21","author":"Certo","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2025112417481764300_bib62","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"de la Cruz-L\u00f3pez","year":"2019","journal-title":"Front Oncol"},{"key":"2025112417481764300_bib63","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","article-title":"Lactate: a metabolic key player in cancer","volume":"71","author":"Hirschhaeuser","year":"2011","journal-title":"Cancer Res"},{"key":"2025112417481764300_bib64","doi-asserted-by":"crossref","first-page":"3005\u2013","DOI":"10.1200\/JCO.2022.40.16_suppl.3005","article-title":"A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors","volume":"40","author":"Yarchoan","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-3551\/3277238\/can-22-3551.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/9\/1543\/3326086\/1543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/9\/1543\/3326086\/1543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:49:19Z","timestamp":1764024559000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/83\/9\/1543\/726057\/Polyunsaturated-Fatty-Acid-Bound-Fetoprotein"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":64,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,2,27]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-22-3551","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.27027308","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27027308.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30700075","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6626123","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22730621.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6626123.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6626123.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22730621","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}